Pharmafile Logo

Case study: Opportunity Assessment for a Rare Disease Product in Emerging Markets

January 6, 2016 | emerging markets, haematology 

Using in-depth-interviews to determine how to maximise the commercial opportunities in different emerging markets

We have recently produced a guide to conducting effective market research in rare diseases, based on our experience in a broad number of disease areas.

Our client had a product indicated for a rare Haematology disease. Whilst this product was successfully launched in over 40 countries globally, it had a limited presence in many emerging markets. Our client needed to conduct market research in order to determine how to maximise the commercial opportunities in each of these different emerging markets.

Read the full case study here:
http://www.researchpartnership.com/news/2015/11/case-study-opportunity-assessment-for-a-rare-disease…  

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when...

Wargaming in HCV

The challenge:Our client had a product ready for launch in the HCV landscape. A number of new competitor products were expected to alter the market dynamics. Given the stage of...

Living with Lupus: Breaking the Silence

Published in eyeforpharma July 2017 by Mariel Metcalfe

Demystifying human-centred design: the application of iterative, human-centric approaches in global health market research

One of the biggest buzz topics in the global health community over the last couple of years has been human-centred design, also referred to as behaviour-centred design. In this blog...

In the news: What will the UK’s recent general election result and ongoing Brexit negotiations mean for DfID funding for global health?

The UK’s Department for International Development (DfID) was established in 1997 with a mandate to tackle world poverty. Since its inception, it has played a major role in the global...

EphMRA 2017 round up

We were delighted to present, exhibit and sponsor this year’s EphMRA Annual Conference in Amsterdam, Netherlands.

Taking a hybrid qualitative-quantitative approach to research

Directors Phil Rosenberg and Chris Gaj discuss ways to achieve qualitative insights with quantitative precision and the benefits of a hybrid approach.Watch the video: https://www.researchpartnership.com/news/2017/06/video-taking-a-hybrid-qualitative-quantitative-appr...

20th anniversary celebrations

We recently celebrated our 20th year anniversary with parties for our employees across the globe.Find out more and view the photos https://www.researchpartnership.com/news/2017/06/20th-anniversary-party-photos/

Pharma CI Asia Conference & Exhibition 2017

13-14 July 2017, Singapore

Director Richard Head is joint winner of the 2017 EphMRA President’s Award

We are delighted to announce that Research Partnership’s Richard Head is joint winner of the 2017 EphMRA President's Award for his contribution to pharmaceutical market research